Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2012-07-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that brain structural changes can be detected in neonatal life. The investigators hypothesize that offspring of schizophrenic patients will have higher rates of brain structural changes in the neonatal period. The investigators propose to study early development of fetuses in offspring of patients with schizophrenia. The study is a multi-center prospective trial.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
healthy parents
imaging follow up: MRI scan
.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
imaging follow up: Ultrasonographic examination
schizophrenic parents
imaging follow up: MRI scan
.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
imaging follow up: Ultrasonographic examination
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
imaging follow up: MRI scan
.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
imaging follow up: Ultrasonographic examination
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Past history or present occurrence of major neurologic or somatic illness
* Genetic disease
* Other psychiatric disorders other than schizophrenia such as Mental retardation
* Bipolar Disorder and Delusional Disorder
18 Years
60 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tel-Aviv Sourasky Medical Center
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nivi Rotenberg, M.D.
Role: PRINCIPAL_INVESTIGATOR
International Diabetes Federation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abarbanel Mental Health Centre
Bat Yam, , Israel
Beer Yaacov Mental health Centre
Beer Yaakov, , Israel
Shalvata mental health centre
Hod HaSharon, , Israel
Edith Wolfson Medical Centre
Holon, , Israel
Geha mental health centre
Petah Tikva, , Israel
Brill outpatient clinic
Tel Aviv, , Israel
Sourasky Medical Centre
Tel Aviv, , Israel
Chaim Sheba medical centre
Tel Litwinsky, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ido Lurie, M.D.
Role: primary
Faina Bar, M.D.
Role: primary
Gustavo Malinger, M.D.
Role: primary
Avi Weizman, Proffesor
Role: primary
Nitsa Nakash, M.D.
Role: primary
Miki Bloch, M.D.
Role: primary
Judith Reidman, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18105
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
TASMC-11-NR-0192-11-CTIL
Identifier Type: -
Identifier Source: org_study_id